Mirtazapine (Remeron) for PTSD in the Elderly
Mirtazapine is not a first-line agent for PTSD treatment in elderly patients, but may be considered as an alternative when SSRIs are contraindicated or poorly tolerated, particularly when comorbid insomnia, depression, or poor appetite are present. The evidence for mirtazapine's efficacy in PTSD is limited and conflicting, with the largest controlled trial showing no benefit over placebo 1.
Evidence for Efficacy in PTSD
The evidence base for mirtazapine in PTSD is weak:
The only adequately powered RCT (n=78 veterans) found no significant difference between mirtazapine and placebo on the primary PTSD outcome measure during the 8-week controlled phase 1. However, secondary outcomes showed some improvement on the Clinical Global Impressions scale, and an open-label extension demonstrated symptom reduction.
Smaller open-label studies suggested potential benefit, with one showing 50% of patients achieving ≥50% symptom reduction 2, and another Australian study (n=13) showing CAPS score reduction from 87.5 to 64.4 3. These are low-quality, uncontrolled data.
A 2022 Cochrane review found low-certainty evidence that mirtazapine improved PTSD symptoms (RR 0.45,95% CI 0.22 to 0.94), with 65% responding versus 22% on placebo, but this was based on only one small study 4.
A 2026 meta-analysis found mirtazapine may have potential as an augmentation strategy in PTSD, particularly when rapid effect or sleep improvement is needed 5.
Dosing in the Elderly
Start at 7.5 mg at bedtime and titrate slowly to a maximum of 30 mg at bedtime 6, 7. The FDA label specifies:
- Initial dose: 7.5 mg at bedtime (lower than the standard 15 mg starting dose for younger adults)
- Titration: Increase gradually based on response and tolerability
- Maximum dose: 30 mg at bedtime (lower than the 45 mg maximum in younger adults)
- Timing: Administer once daily, preferably in the evening prior to sleep 7
The rationale for lower dosing in elderly patients is critical: elderly males have 40% lower clearance and elderly females have 10% lower clearance compared to younger adults 7. Additionally, the elimination half-life is prolonged (20-40 hours), with females exhibiting significantly longer half-lives (37 hours vs 26 hours in males) 7.
Monitoring Requirements
Monitor closely for:
- Orthostatic hypotension: Mirtazapine antagonizes peripheral α1-adrenergic receptors and histamine H1 receptors, increasing fall risk in elderly patients 7
- Somnolence: The prominent sedative effects may impair judgment and motor skills 7
- Weight gain and increased appetite: Common adverse effects that require monitoring 6, 7
- Hyponatremia: Can occur with serotonergic antidepressants, particularly problematic in elderly 7
- Cognitive impairment: Assess for worsening confusion or delirium
- Hepatic and renal function: Dose reduction may be needed if moderate-to-severe impairment develops 7
Special Considerations for Elderly Patients
Mirtazapine is listed as a preferred antidepressant for older patients with depression 8, which makes it a reasonable choice when PTSD co-occurs with depression. The drug's properties may be advantageous in elderly PTSD patients:
- Promotes sleep: Beneficial for PTSD-related insomnia 6, 9
- Increases appetite and weight: Helpful for elderly patients with poor oral intake 6
- Well tolerated: Generally fewer discontinuations due to adverse effects compared to SSRIs 6
However, avoid in patients with cognitive impairment or high fall risk due to sedation and orthostatic hypotension.
Dose Adjustments
Reduce dose in patients with:
- Hepatic impairment: Clearance decreased by ~30% 7
- Moderate-to-severe renal impairment: Clearance reduced by 30-50% depending on GFR 7
- Concurrent use of CYP3A4 inhibitors (e.g., ketoconazole) or cimetidine: May increase mirtazapine levels by >50% 7
Increase dose cautiously if using concurrent CYP3A4 inducers (e.g., carbamazepine, phenytoin), which can reduce mirtazapine levels by ~60% 7.
Duration of Treatment
A full therapeutic trial requires at least 4-8 weeks at the maximum tolerated dose 6. If no improvement occurs after 8 weeks at adequate dosing, consider switching to an evidence-based first-line agent.
When discontinuing, taper gradually over 10-14 days to limit withdrawal symptoms 6, 7.
Clinical Algorithm
- First-line: Consider SSRIs (sertraline preferred in elderly) for PTSD unless contraindicated
- Alternative: Use mirtazapine if:
- SSRIs failed or not tolerated
- Comorbid depression with insomnia and poor appetite
- Patient cannot tolerate SSRI side effects (sexual dysfunction, GI upset)
- Start 7.5 mg at bedtime
- Assess response at 2 weeks: If tolerated but insufficient response, increase to 15 mg
- Reassess at 4 weeks: If tolerated but insufficient response, increase to 30 mg (maximum for elderly)
- Continue for 4-8 weeks at maximum tolerated dose before declaring treatment failure
- Monitor: Blood pressure (orthostatic), weight, sodium, falls, cognitive status
Important Caveats
- Prazosin (1-10 mg at bedtime) has stronger evidence (Level A) specifically for PTSD-associated nightmares 10, and should be considered as adjunctive therapy if nightmares are prominent
- SSRIs remain first-line pharmacotherapy for PTSD based on moderate-certainty evidence 4
- Benzodiazepines should be avoided despite common use, as they are not recommended in guidelines 11
- The evidence for mirtazapine monotherapy in PTSD is insufficient; it may be more appropriate as augmentation or when targeting comorbid symptoms 5, 1